1. Home
  2. KXIN vs HSCS Comparison

KXIN vs HSCS Comparison

Compare KXIN & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KXIN

Kaixin Auto Holdings

HOLD

Current Price

$5.17

Market Cap

7.0M

ML Signal

HOLD

Logo Heart Test Laboratories Inc.

HSCS

Heart Test Laboratories Inc.

HOLD

Current Price

$2.18

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KXIN
HSCS
Founded
2015
2007
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0M
6.4M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
KXIN
HSCS
Price
$5.17
$2.18
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
100.3K
45.8K
Earning Date
11-26-2019
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.84
EPS
N/A
N/A
Revenue
N/A
$4,319.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$1.63
52 Week High
$22.00
$3.93

Technical Indicators

Market Signals
Indicator
KXIN
HSCS
Relative Strength Index (RSI) 48.10 48.69
Support Level $4.05 $2.16
Resistance Level $5.86 $2.76
Average True Range (ATR) 0.31 0.21
MACD -0.04 -0.00
Stochastic Oscillator 58.98 63.09

Price Performance

Historical Comparison
KXIN
HSCS

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.

About HSCS Heart Test Laboratories Inc.

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.

Share on Social Networks: